CLARITY News and Research

RSS

The lipid-exchanged, anatomically rigid, imaging/immunostaining compatible, tissue hydrogel (CLARITY) method was initially designed in 2013 by Chung and Deisseroth at the Stanford University School of Medicine. Using this process, post-mortem organs can be labeled for proteins and nucleic acids, enabling analysis of intact samples to create detailed 3D images.

Trius commences oral torezolid phosphate Phase 3 clinical study for ABSSSI

Trius Therapeutics, Inc. announced that the first patient has been dosed in its Phase 3 clinical study of the oral dosage form of torezolid phosphate for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The double-blind, active control, pivotal study is designed to compare the efficacy and safety of once-daily oral administration of 200 milligrams of torezolid phosphate for six days of treatment with the efficacy and safety of twice-daily oral administration of 600 milligrams of linezolid (Zyvox®) for 10 days of treatment.

30 Aug 2010

Authorities arrest more than 80 people, seize 10 tons of counterfeit meds in E. Africa

Authorities have arrested more than 80 people and seized 10 tons of counterfeit medicines across six East African countries, the international police agency Interpol announced Thursday, United Press International reports (8/26).

27 Aug 2010

Restat announces signing of PEBA as latest Align cost-plus pricing model client

Restat, the nation's largest independent pharmacy benefits manager has announced the signing of the Public Employee Benefits Alliance as its latest Align cost-plus pricing model client. PEBA, an organization formed by several Texas government employers, cooperatively purchases employee benefits -- including health care benefits -- on behalf of the local government entities.

26 Aug 2010

Inspire Pharmaceuticals, Allergan sign amended agreement for ophthalmic formulations

Inspire Pharmaceuticals, Inc. announced today it has entered into an Amended and Restated License, Development and Marketing Agreement with Allergan, Inc., which revises terms related to the PROLACRIA (diquafosol tetrasodium ophthalmic solution) 2% development program and Inspire's right to receive revenues from Allergan based on net sales of RESTASIS (cyclosporine ophthalmic emulsion) 0.05% and any other human ophthalmic formulations of cyclosporine owned or controlled by Allergan.

25 Aug 2010

Urologix 2010 fourth quarter net loss decreases 28.9% to $0.04 per share

Urologix, a medical device company that develops, manufactures and markets minimally invasive Cooled ThermoTherapy™ technology to urologists to provide a durable and effective in-office treatment for patients suffering from benign prostatic hyperplasia (BPH), today reported financial results for its fourth quarter ended June 30, 2010 and for fiscal year 2010.

25 Aug 2010

MWellA online community promotes awareness on mental disorders

Mental health is a hot button issue in today's society. People worry about the safety, cost, and multiple side-effects of anti-depressants and other psychoactive medications. Everyone wants to find peace of mind, contentment and happiness, but for many this struggle can prove overwhelming. Author and world organic food movement pioneer Paul Huljich addresses this issue in a Ning community he created for his organization MWellA (Mind Wellness Awareness)

24 Aug 2010

Scientists discover genetic flaw that causes facioscapulohumeral muscular dystrophy

Nearly two decades after they identified the specific genetic flaw that causes a common type of muscular dystrophy, scientists believe they have figured out how that flaw brings about the disease. The finding by an international team of researchers settles a longstanding question about the roots of facioscapulohumeral muscular dystrophy or FSHD.

20 Aug 2010

Daily dose of aspirin may reduce prostate cancer risk: US Study

A US study has found that a daily dose of aspirin may reduce the risk of prostate cancer, but Cancer Research UK has noted that regular use of aspirin can cause serious side-effects and should not be undertaken unless recommended by a doctor.Several previous studies have looked at the possibility of an association between aspirin use and a reduced risk of prostate cancer.In the latest study, scientists at the Fred Hutchinson Cancer Research Centre in Seattle, led by Dr Janet Stanford, looked at data on 1,001 prostate cancer patients and a similar number of cancer-free volunteers.

16 Aug 2010

FDA grants LifeCycle Pharma SPA for LCP-Tacro pivotal Phase 3 study in 'de novo' kidney transplant patients

LifeCycle Pharma A/S today announced receipt of agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment of its pivotal Phase 3 study, Study 3002, for LCP-Tacro in patients, who have just received a kidney transplant.

12 Aug 2010

Scientists develop new imaging technique to create three-dimensional images of melanoma

Melanoma is one of the less common types of skin cancer but it accounts for the majority of the skin cancer deaths (about 75 percent).The five-year survival rate for early stage melanoma is very high (98 percent), but the rate drops precipitously if the cancer is detected late or there is recurrence.So a great deal rides on the accuracy of the initial surgery, where the goal is to remove as little tissue as possible while obtaining "clean margins" all around the tumor.So far no imaging technique has been up to the task of defining the melanoma's boundaries accurately enough to guide surgery.Instead surgeons tend to cut well beyond the visible margins of the lesion in order to be certain they remove all the malignant tissue.Two scientists at Washington University in St. Louis have developed technologies that together promise to solve this difficult problem.

12 Aug 2010

Thomson Reuters earns Communication Seal from DALBAR for Personal Health Insights

Thomson Reuters has earned the Communication Seal from DALBAR, Inc. for its Personal Health Insights, an easy-to-read-and-understand health statement for individuals.

10 Aug 2010

Scientific paper explains impact of visual cycle modulation in neurovascular retinopathy

Acucela, a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, announced today that a scientific paper co-authored by Ryo Kubota, M.D., Ph.D., chairman, president and chief executive officer of Acucela, has been published in Experimental Eye Research. The paper, "Visual Cycle Modulation in Neurovascular Retinopathy" was also co-authored by scientists from Children's Hospital and Harvard Medical School in Boston and demonstrates for the first time the impact of treatment with a visual cycle modulator (VCM) on retinopathy in an immature eye.

10 Aug 2010

Medical Action Industries first-quarter fiscal 2011 net sales decrease 5.5%

Medical Action Industries Inc., a leading supplier of medical and surgical disposable products, today reported fiscal results for the first quarter ended June 30, 2010.

9 Aug 2010

Recent releases in Global Health

According to a Lancet Comment, "alcohol remains conspicuously absent from the larger field of research and programming in HIV and substance use. ... Patterns of hazardous alcohol consumption prevail in countries with the most severe HIV epidemics, notably eastern and southern Africa." In addition, "hazardous drinking patterns also dominate in the concentrated epidemics of eastern Europe and Asia, where alcohol use by injecting drug users and other marginalised groups might be an additional barrier to effective efforts to prevent HIV infection."

7 Aug 2010

Today's OpEds: Reform battles, state challenges to law loom over elections

In its rush to blunt public opposition to the newly enacted health reform law, the Obama administration is on a collision course with Republicans as the November midterm elections loom. On behalf of his reform agenda, President Barack Obama in recent weeks bypassed the Senate to make a "recess" appointment of a new Medicare and Medicaid administrator, Donald Berwick, while Congress was adjourned for the Independence Day holiday.

7 Aug 2010

FDA issues comprehensive evaluations that address key objectives of agency's public health mission

The U.S. Food and Drug Administration today issued two comprehensive evaluations containing recommendations that address three key objectives of the agency's public health mission as it relates to medical devices – foster device innovation, create a more predictable regulatory environment, and enhance device safety.

5 Aug 2010

Triple-S Management second-quarter total consolidated operating revenues up 8.2%

Triple-S Management Corporation, the largest managed care company in Puerto Rico, today announced consolidated revenues of $522.7 million and operating income of $26.1 million for the three months ended June 30, 2010. Net income of $15.1 million, or $0.51 per diluted share, includes an after tax net loss of $4.5 million, or $0.16 per share, related to net realized and unrealized losses on investments and derivatives.

4 Aug 2010

MAP Pharmaceuticals reports net loss of $12.5M for second-quarter 2010

MAP Pharmaceuticals, Inc. today announced financial results for the second quarter ended June 30, 2010.

3 Aug 2010

Natus Medical second-quarter revenue increases to $52.7 million

Natus Medical Incorporated today announced financial results for the three and six months ended June 30, 2010.

29 Jul 2010

NDS Surgical Imaging introduces ConnectOR G2 visualization and informatics platform

NDS Surgical Imaging (NDSsi) today launched its next-generation visualization and informatics platform—the ConnectOR G2—with production units now shipping to customers. Based on the NDSsi technology vision of Medical Visualization Informatics (MVI), ConnectOR G2 medical-grade products are leading the industry in procedural efficacy by offering the unique ability to connect the realms of PACS imaging, surgical video and medical informatics.